@prefix this: <
http://bio2rdf.org/drugbank:DB08870_nanopub.RA6jKwHr8EBhzwRD5G8Cu_aXBkoqry1mFpANwoks3qz94
> .
@prefix sub: <
http://bio2rdf.org/drugbank:DB08870_nanopub.RA6jKwHr8EBhzwRD5G8Cu_aXBkoqry1mFpANwoks3qz94#
> .
@prefix prov: <
http://www.w3.org/ns/prov#
> .
@prefix dct: <
http://purl.org/dc/terms/
> .
@prefix pav: <
http://purl.org/pav/
> .
@prefix orcid: <
http://orcid.org/
> .
@prefix codebase: <
https://github.com/tkuhn/bio2rdf2nanopub
> .
@prefix version: <
https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349
> .
@prefix instance: <
https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB
> .
@prefix process: <
https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475
> .
@prefix np: <
http://www.nanopub.org/nschema#
> .
@prefix rdfs: <
http://www.w3.org/2000/01/rdf-schema#
> .
@prefix xsd: <
http://www.w3.org/2001/XMLSchema#
> .
@prefix v: <
http://bio2rdf.org/bio2rdf_vocabulary:
> .
@prefix d: <
http://bio2rdf.org/drugbank:
> .
@prefix dv: <
http://bio2rdf.org/drugbank_vocabulary:
> .
@prefix dr: <
http://bio2rdf.org/drugbank_resource:
> .
@prefix dcat: <
http://www.w3.org/ns/dcat#
> .
@prefix npx: <
http://purl.org/nanopub/x/
> .
sub:head
{
this:
np:hasAssertion
sub:assertion
;
np:hasProvenance
sub:provenance
;
np:hasPublicationInfo
sub:publicationInfo
;
a
np:Nanopublication
.
}
sub:assertion
{
d:DB08870
v:identifier
"DB08870" ;
v:namespace
"drugbank" ;
v:uri
"http://bio2rdf.org/drugbank:DB08870" ;
v:x-identifiers.org
<
http://identifiers.org/drugbank/DB08870
> ;
dv:drugbank-id
"DB08870" ;
dv:x-atc
<
http://bio2rdf.org/atc:L01XC12
> ;
dv:x-cas
<
http://bio2rdf.org/cas:914088-09-8
> ;
dv:x-kegg
<
http://bio2rdf.org/kegg:D09587
> ;
dv:x-wikipedia
<
http://bio2rdf.org/wikipedia:Brentuximab_vedotin
> ;
dct:description
"Brentuximag vedotin or Adcetris® is an antibody-drug conjugate that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Brentuximag vedotin was approved in 2011, and in January 2012, the drug label was revised to include a boxed warning of progressive multifocal leukoencephalopathy and death following JC virus infection."@en ;
dct:identifier
"drugbank:DB08870" ;
dct:title
"Brentuximab vedotin"@en ;
a
dv:Drug
;
rdfs:label
"Brentuximab vedotin [drugbank:DB08870]"@en ;
rdfs:seeAlso
<
http://www.drugbank.ca/drugs/DB08870
> , <
http://www.drugs.com/mtm/brentuximab-vedotin.html
> , <
http://www.rxlist.com/adcetris-drug.htm
> .
}
sub:provenance
{
sub:assertion
prov:wasDerivedFrom
<
http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz
> .
dr:bio2rdf.dataset.drugbank.R3
dcat:distribution
<
http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz
> .
<
http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz
>
dct:created
"2015-01-09T17:00:50-05:00"^^
xsd:dateTime
;
prov:wasDerivedFrom
<
http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00
> .
<
http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00
>
pav:retrievedOn
"2014-11-12T07:57:03-05:00"^^
xsd:dateTime
;
prov:wasDerivedFrom
<
http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip
> .
<
http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip
>
prov:wasAttributedTo
<
http://drugbank.ca
> .
}
sub:publicationInfo
{
sub:signature.MCwCFHWPqE1kD0Pw
npx:hasPublicKey
"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" ;
npx:hasSignature
"MCwCFHWPqE1kD0PwNRvyyVOLYWgJq8gwAhQC+WRQ2JjnNyHvuiA6SFuPeAPgwQ==" ;
npx:signedBy
instance:
.
this:
dct:created
"2018-03-30T11:10:58.295+02:00"^^
xsd:dateTime
;
dct:license
<
https://creativecommons.org/licenses/by-nc/4.0/
> ;
npx:hasSignatureElement
sub:signature.MCwCFHWPqE1kD0Pw
;
prov:wasGeneratedBy
process:
.
instance:
prov:specializationOf
codebase:
;
prov:wasAttributedTo
orcid:0000-0002-1267-0234
.
process:
dct:identifier
"7720f136-841b-4851-a6e4-ad20a409a475" ;
prov:used
version:
;
prov:wasAssociatedWith
instance:
;
prov:wasStartedBy
orcid:0000-0002-1267-0234
.
version:
dct:isVersionOf
codebase:
;
pav:version
"eda7951a5f6c622c5d2132f50c3093138484a349" ;
prov:wasAttributedTo
orcid:0000-0002-1267-0234
.
}